Using tissue plasminogen activator to treat glaucoma
Official title: Tissue plasminogen activator for the treatment of glaucoma
Funded at VA New York Harbor Hlthcare/sys/brooklyn · NIH-11065469 · Data updated 2026-11-12
This study is looking at how a medication called tPA might help people with open angle glaucoma by improving fluid drainage in the eye, which could lower eye pressure and help protect against vision loss.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA New York Harbor Hlthcare/sys/brooklyn NIH-funded |
| Lab location | 1 site (Brooklyn, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01RX004255-03 |
| Project ID | NIH-11065469 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with open angle glaucoma, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with other types of glaucoma or those who do not have elevated intraocular pressure may not benefit from this research.
What this research studies
This research investigates the use of tissue plasminogen activator (tPA) as a potential treatment for open angle glaucoma (OAG), a condition that can lead to blindness. The study aims to understand how tPA can improve the outflow of aqueous humor, which is crucial for managing intraocular pressure (IOP) in patients with OAG. By examining the safety and efficacy of tPA and its inactive form, the research seeks to provide a new therapeutic approach that targets the underlying pathology of the disease. Patients may benefit from a treatment that not only lowers IOP but also enhances the natural drainage of fluid from the eye.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that effectively manages glaucoma and reduces the risk of blindness.
How similar studies have gone: Previous research has shown promising results using tPA in animal models, indicating potential for success in human applications.
Where this research is happening
-
VA New York Harbor Hlthcare/sys/brooklyn
Brooklyn, United States Active
Researchers
- Principal investigator: Danias, John — VA New York Harbor Hlthcare/sys/brooklyn
- Study coordinator: Danias, John
Related research
Other NIH-funded projects on the same topics.
-
IOP and CSF Pressure in Glaucoma Risk
This grant studies how eye pressure and cerebrospinal fluid pressure together influence glaucoma risk and vision loss.
-
Comparing tube positions in glaucoma implants to protect corneal cells
This trial compares two tube placements for glaucoma drainage implants to see which better protects corneal cells and controls eye pressure in people with uncontrolled glaucoma.
-
Automated topographic test for glaucoma detection and progression
A new automated method uses topographic structure-function mapping to help diagnose glaucoma earlier and track its progression in patients.
-
Using AI on eye scans and genes to predict glaucoma risk
This project uses artificial intelligence on eye scans, vision tests, and genetic information to find people most likely to develop or have worsening glaucoma.
-
AI-based glaucoma screening in community health centers
A new, easy-to-use AI screening approach will be tested in federally funded health centers to help identify people at risk for glaucoma, especially in communities with higher risk.
-
Understanding how glaucoma genes control eye cell function
A long-term research project will study how genetic factors affect eye cells in adults with glaucoma to uncover new ideas for protecting vision.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.